Blockchain Registration Transaction Record

GeoVax Accelerates GEO-MVA Vaccine Development Amid Global Mpox Threat

GeoVax advances GEO-MVA vaccine for Mpox and smallpox, with EMA's expedited path, aiming to diversify global vaccine supply and enhance pandemic preparedness.

The expedited development and potential commercialization of GeoVax's GEO-MVA vaccine represent a pivotal advancement in global health security. With Mpox cases on the rise and the existing limitations in vaccine supply, GeoVax's initiative could significantly enhance the world's preparedness against not only Mpox but also other high-consequence threats like smallpox. This development matters because it promises to diversify vaccine supply options, reduce dependency on single-source solutions, and ultimately, save lives by providing timely and effective immunization against deadly diseases.